Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.

Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A

Open source

DOI: 10.1007/s10549-010-1257-5
Published: 2011 Feb
Container: Breast cancer research and treatment
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-010-1257-5,
  title = {Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.},
  author = {Amadori D and Silvestrini R and De Lena M and Boccardo F and Rocca A and Scarpi E and Schittulli F and Brandi M and Maltoni R and Serra P and Ponzone R and Biglia N and Gianni L and Tienghi A and Valerio MR and Bonginelli P and Amaducci L and Faedi M and Baldini E and Paradiso A},
  year = {2011},
  journal = {Breast cancer research and treatment},
  doi = {10.1007/s10549-010-1257-5},
  url = {https://doi.org/10.1007/s10549-010-1257-5}
}

RIS

TY  - JOUR
TI  - Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
AU  - Amadori D
AU  - Silvestrini R
AU  - De Lena M
AU  - Boccardo F
AU  - Rocca A
AU  - Scarpi E
AU  - Schittulli F
AU  - Brandi M
AU  - Maltoni R
AU  - Serra P
AU  - Ponzone R
AU  - Biglia N
AU  - Gianni L
AU  - Tienghi A
AU  - Valerio MR
AU  - Bonginelli P
AU  - Amaducci L
AU  - Faedi M
AU  - Baldini E
AU  - Paradiso A
PY  - 2011
JO  - Breast cancer research and treatment
DO  - 10.1007/s10549-010-1257-5
UR  - https://doi.org/10.1007/s10549-010-1257-5
ER  -

APA

D, A., R, S., M, D. L., F, B., A, R., E, S., F, S., M, B., R, M., P, S., R, P., N, B., L, G., A, T., MR, V., P, B., L, A., M, F., E, B., & A, P. (2011). Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-010-1257-5

Source records

pubmed · retrieved 2026-09-26T20:47:29.684Z